Please Wait a Moment
X

CTS History

01Dec

Babesia

SuperUser Account |01 Dec, 2015 | Return|

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

Dengue Testing

Dengue Testing

CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.

Read More >
CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...

Read More >

Research Consortium

CTS Research Consortium was established to further CTS’s leadership in infectious disease research....

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...

Read More >
CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >
Source plasma partners

Source plasma partners

By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...

Read More >